Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Advanced Endometrial Carcinoma: early-phase trial registry

5 of 7 indexed Advanced Endometrial Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 5 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Advanced Endometrial Carcinoma: 7 US clinical trials tracked, 5 recruiting.

Advanced Endometrial Carcinoma is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 5 of these trials.

Enrollment posture brief

Registry condition advanced-endometrial-carcinoma

OPEN 5 | RECR 71% | LATE 1 | EARLY 6 | RANK #2497 | SPON 5

Nearest open-share peer: Advanced Prostate Cancer (71% recruiting · 7 trials)

ACL Tear71.4%Advanced Endometrial Car (th…71%ACL57.1%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Advanced Endometrial Carcinoma

Advanced Endometrial Carcinoma lists 5 open slots (71% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Advanced Endometrial Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Advanced Endometrial Carcinoma is recruiting above its size-band peers.

    5 of 7 indexed trials (71.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Advanced Endometrial Carcinoma research.

    National Cancer Institute (NCI) accounts for 5 of 7 trials (71.4%). 2 distinct sponsors appear on at least one study for this condition label.

  3. Most Advanced Endometrial Carcinoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 54 among the 7 trials that report a genuine target (sentinel values excluded). 6 of those (85.7%) plan for fewer than 100 participants.

  4. Advanced Endometrial Carcinoma research is mostly interventional.

    7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 21Phase 31

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 3 255 participants

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

National Cancer Institute (NCI)

NCT07198074

RECRUITING Phase 1 54 participants

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

M.D. Anderson Cancer Center

NCT05039801

RECRUITING Phase 1 51 participants

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

NCT04704661

RECRUITING Phase 1 43 participants

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

M.D. Anderson Cancer Center

NCT05092373

RECRUITING Phase 1 42 participants

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

National Cancer Institute (NCI)

NCT05691504

ACTIVE NOT RECRUITING Phase 2 82 participants

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

National Cancer Institute (NCI)

NCT03367741

ACTIVE NOT RECRUITING Phase 1 74 participants

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

National Cancer Institute (NCI)

NCT04491942

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 1
Phase 3 1

Named interventions

Most-linked intervention names on Advanced Endometrial Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Computed Tomography Procedure
4 trials
Biospecimen Collection Procedure
4 trials
Biopsy Procedure Procedure
3 trials
Bevacizumab Biological
2 trials
Echocardiography Test Procedure
2 trials
Cabozantinib S-malate Drug
2 trials
Magnetic Resonance Imaging Procedure
2 trials
Elimusertib Drug
1 trials

US sites by state

Facility locations filed on Advanced Endometrial Carcinoma trials. A trial with sites in several states counts in each.

Maryland 5 trials
Texas 3 trials
Illinois 3 trials
California 3 trials
Pennsylvania 2 trials
Ohio 2 trials
New York 2 trials
Missouri 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Advanced Endometrial Carcinoma page

7 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Endometrial Carcinoma condition card totals 7 registered trials; most-linked intervention Computed Tomography; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.